|
1
|
White NJ: Qinghaosu (artemisinin): The
price of success. Science. 320:330–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng J, Chen X, Wang Y, Du Y, Sun Q, Zang
W and Zhao G: Myricetin inhibits proliferation and induces
apoptosis and cell cycle arrest in gastric cancer cells. Mol Cell
Biochem. 408:163–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pearce LV, Petukhov PA, Szabo T, Kedei N,
Bizik F, Kozikowski AP and Blumberg PM: Evodiamine functions as an
agonist for the vanilloid receptor TRPV1. Org Biomol Chem.
2:2281–2286. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma
K, Yokoo Y and Kamiya T: Capsaicin-like anti-obese activities of
evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor
agonist. Planta Med. 67:628–633. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takada Y, Kobayashi Y and Aggarwal BB:
Evodiamine abolishes constitutive and inducible NF-kappaB
activation by inhibiting IkappaBalpha kinase activation, thereby
suppressing NF-kappaB-regulated antiapoptotic and metastatic gene
expression, up-regulating apoptosis, and inhibiting invasion. J
Biol Chem. 280:17203–17212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heo SK, Yun HJ, Yi HS, Noh EK and Park SD:
Evodiamine and rutaecarpine inhibit migration by LIGHT via
suppression of NADPH oxidase activation. J Cell Biochem.
107:123–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen Z, Feng S, Wei L, Wang Z, Hong D and
Wang Q: Evodiamine, a novel inhibitor of the Wnt pathway, inhibits
the self-renewal of gastric cancer stem cells. Int J Mol Med.
36:1657–1663. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang T, Wang Y and Yamashita H: Evodiamine
inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway.
FEBS Lett. 583:3655–3659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shan T, Zhang P, Bi P and Kuang S: Lkb1
deletion promotes ectopic lipid accumulation in muscle progenitor
cells and mature muscles. J Cell Physiol. 230:1033–1041. 2015.
View Article : Google Scholar :
|
|
10
|
Di Marcantonio D, Galli D, Carubbi C,
Gobbi G, Queirolo V, Martini S, Merighi S, Vaccarezza M, Maffulli
N, Sykes SM, et al: PKCε as a novel promoter of skeletal muscle
differentiation and regeneration. Exp Cell Res. 339:10–19. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He K, Hu J, Yu H, Wang L, Tang F, Gu J, Ge
L, Wang H, Li S, Hu P and Jin Y: Serine/threonine kinase 40 (Stk40)
functions as a novel regulator of skeletal muscle differentiation.
J Biol Chem. 292:351–360. 2017. View Article : Google Scholar :
|
|
12
|
Taylor WE, Bhasin S, Artaza J, Byhowe F,
Azam M, Willard DH Jr, Kull FC Jr and Gonzalez-Cadavid N: Myostatin
inhibits cell proliferation and protein synthesis in C2C12 muscle
cells. Am J Physiol Endocrinol Metab. 280:E221–E228. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Q, Shi XE, Song C, Sun S, Yang G and
Li X: BAMBI promotes C2C12 myogenic differentiation by enhancing
Wnt/β-catenin signaling. Int J Mol Sci. 16:17734–17745. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki A, Scruggs A and Iwata J: The
temporal specific role of WNT/β-catenin signaling during
myogenesis. J Nat Sci. 1:e1432015.
|
|
15
|
Armstrong DD and Esser KA:
Wnt/beta-catenin signaling activates growth-control genes during
overload-induced skeletal muscle hypertrophy. Am J Physiol Cell
Physiol. 289:C853–C859. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang J, Mo C, Bonewald L and Brotto M:
Wnt3a and Wnt1 enhance myogenesis of C2C12 myoblasts–potential
mechanisms of osteocyte to muscle cell signaling. The FASEB
Journal. 29(1 Supplement): 947.132015.
|
|
17
|
Zhang L, Shi S, Zhang J, Zhou F and ten
Dijke P: Wnt/β-catenin signaling changes C2C12 myoblast
proliferation and differentiation by inducing Id3 expression.
Biochem Biophys Res Commun. 419:83–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meloche S and Pouysségur J: The ERK1/2
mitogen-activated protein kinase pathway as a master regulator of
the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Andrews JL, Zhang X, McCarthy JJ,
McDearmon EL, Hornberger TA, Russell B, Campbell KS, Arbogast S,
Reid MB, Walker JR, et al: CLOCK and BMAL1 regulate MyoD and are
necessary for maintenance of skeletal muscle phenotype and
function. Proc Natl Acad Sci USA. 107:19090–19095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cadigan KM and Nusse R: Wnt signaling: A
common theme in animal development. Genes Dev. 15:3286–3305. 1997.
View Article : Google Scholar
|
|
22
|
Brack AS, Conboy IM, Conboy MJ, Shen J and
Rando TA: A temporal switch from notch to Wnt signaling in muscle
stem cells is necessary for normal adult myogenesis. Cell Stem
Cell. 2:50–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jho EH, Zhang T, Domon C, Joo CK, Freund
JN and Costantini F: Wnt/beta-catenin/Tcf signaling induces the
transcription of Axin2, a negative regulator of the signaling
pathway. Mol Cell Biol. 22:1172–1183. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick
R, Hanash S, Cho KR and Fearon ER: Activation of AXIN2 expression
by beta-catenin-T cell factor. A feedback repressor pathway
regulating Wnt signaling. J Biol Chem. 277:21657–21665. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu L, Wang Z, Huang M, Li Y, Zeng K, Lei
J, Hu H, Chen B, Lu J, Xie W and Zeng S: Evodia alkaloids suppress
gluconeogenesis and lipogenesis by activating the constitutive
androstane receptor. Biochim Biophys Acta. 1859:1100–1111. 2016.
View Article : Google Scholar
|
|
26
|
Fei XF, Wang BX, Li TJ, Tashiro S, Minami
M, Xing DJ and Ikejima T: Evodiamine, a constituent of Evodiae
Fructus, induces anti-proliferating effects in tumor cells. Cancer
Sci. 94:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang ZG, Chen AQ and Liu B:
Antiproliferation and apoptosis induced by evodiamine in human
colorectal carcinoma cells (COLO-205). Chem Biodivers. 6:924–933.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen MC, Yu CH, Wang SW, Pu HF, Kan SF,
Lin LC, Chi CW, Ho LLT, Lee CH and Wang PS: Anti-proliferative
effects of evodiamine on human thyroid cancer cell line ARO. J Cell
Biochem. 110:1495–1503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and
Wang PS: Anti-proliferative effects of evodiamine on human prostate
cancer cell lines DU145 and PC3. J Cell Biochem. 101:44–56. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shyu KG, Lin S, Lee CC, Chen E, Lin LC,
Wang BW and Tsai SC: Evodiamine inhibits in vitro angiogenesis:
Implication for antitumorgenicity. Life Sci. 78:2234–2243. 2006.
View Article : Google Scholar
|
